The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Glycotest CEO discusses University of Georgia partnership for early liver cancer detection
MP3•Jakson koti
Manage episode 443970392 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Charles Swindell, the CEO of Glycotest, a EMV Capital portfolio company, talked with Proactive's Stephen Gunnion about the company’s progress in liver disease diagnostics, specifically its new partnership with the University of Georgia’s Complex Carbohydrate Research Center (CCRC). Swindell highlighted Glycotest’s focus on detecting early-stage liver cancer using their HCC Panel blood test, which aims to address current limitations in liver cancer diagnostics that often miss early-stage cases. "Our flagship test is the HCC Panel for curable early-stage liver cancer," Swindell noted, explaining how the test could detect cases missed by standard tests. Swindell emphasised the partnership with the University of Georgia CCRC as essential for finalising the commercial platform, which will use the expertise of CCRC in carbohydrate-derived biomarkers for liver disease. With 3.1 million potential test candidates in the US alone and an additional 380 million globally, the market opportunity is vast. "We believe that we are well differentiated from competitors," he added, pointing to the unique biomarkers Glycotest employs. To hear more about Glycotest’s plans for commercialization and how its technology could impact liver disease diagnosis, watch the full interview. Visit Proactive’s YouTube channel for more updates, and don’t forget to like, subscribe, and turn on notifications for our latest videos. #Glycotest #LiverCancer #LiverDisease #CancerDiagnostics #CharlesSwindell #HCCPanel #ProactiveInvestors #MedicalInnovation #UGAPartnership #BiomarkerResearch #HealthTech #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 jaksoa
MP3•Jakson koti
Manage episode 443970392 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Charles Swindell, the CEO of Glycotest, a EMV Capital portfolio company, talked with Proactive's Stephen Gunnion about the company’s progress in liver disease diagnostics, specifically its new partnership with the University of Georgia’s Complex Carbohydrate Research Center (CCRC). Swindell highlighted Glycotest’s focus on detecting early-stage liver cancer using their HCC Panel blood test, which aims to address current limitations in liver cancer diagnostics that often miss early-stage cases. "Our flagship test is the HCC Panel for curable early-stage liver cancer," Swindell noted, explaining how the test could detect cases missed by standard tests. Swindell emphasised the partnership with the University of Georgia CCRC as essential for finalising the commercial platform, which will use the expertise of CCRC in carbohydrate-derived biomarkers for liver disease. With 3.1 million potential test candidates in the US alone and an additional 380 million globally, the market opportunity is vast. "We believe that we are well differentiated from competitors," he added, pointing to the unique biomarkers Glycotest employs. To hear more about Glycotest’s plans for commercialization and how its technology could impact liver disease diagnosis, watch the full interview. Visit Proactive’s YouTube channel for more updates, and don’t forget to like, subscribe, and turn on notifications for our latest videos. #Glycotest #LiverCancer #LiverDisease #CancerDiagnostics #CharlesSwindell #HCCPanel #ProactiveInvestors #MedicalInnovation #UGAPartnership #BiomarkerResearch #HealthTech #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 jaksoa
All episodes
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.